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INTRODUCTION 
                     Metastatic brain tumors are one of the common intracranial 
neoplasms encountered in Neurosurgical practice. 8-10% of adults with cancer will 
develop symptomatic metastases during  life5. About 20% of patients with systemic 
malignancy develop cerebral metastases when patients survives upto one to two 
years.   Most cases of brain metastases remain unreported. Majority of brain 
metastasis arise from one of the two common sites: lung cancer and breast 
cancer21,33.The frequency of metastatic brain tumors is increasing because of 
superior imaging modalities and earlier detection and treatment and also longer 
survival after primary cancer diagnosis  because of  more effective treatment of 
systemic disease14.  Still the number of reported cases in India is only the tip of 
iceberg, of the actual incidence of metatases in brain.  
              Appropriate management of patients with brain metastases requires an 
assessment of independent prognostic factors in order to maximize survival and 
neurological function while avoiding unnecessary treatments.  
             There is no comprehensive study in Indian population regarding the 
behavior of brain metastases and various prognostic factors. Although the reported 
cases of cerebral metastasis are only a small percentage of the actual incidence in 
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the society, this Institution being a tertiary referral centre and has both 
Neurosurgery department and Radiation oncology department , studying the 
incidence and other epidemiological factors may closely reflect  the actual situation 
in the society. So in this study an attempt has been made to study the behavior, 
distribution and various factors affecting the survival in patients with brain 
metastases. 
            Moreover in this study ,the previously studied  variables like Karnofsky 
performance status ,age ,  number of metastases, systemic disease activity, source 
of primary, time between primary onset to brain metastases as individual 
prognostic factors were analyzed and also many new factors like edema in imaging 
appearance, treatment modality and their impact on survival were also studied. 
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LITERATURE   REVIEW 
                    Brain metastases are one of the common intracranial space 
occupying lesions. With the increasing survival of patients with systemic disease, 
the incidence of the most brain metastases from  common cancers (lung, breast, 
melanoma, renal and colon) is thought to be rising. Autopsy data show that the 
frequency of brain metastases in patients dying from cancer varies from 20 to 50%, 
and may be higher if dural, leptomeningeal, or spinal metastases are taken into 
account14 .The most common source of brain metastases in males is lung cancer 
and in females is breast cancer14, 24 . 
INCIDENCE 
Metastatic brain tumors account for about 24-45% of all cancer patients5. The 
incidence of metastatic brain tumors exceeds that of primary brain tumors, 
accounting for 50% of total brain tumors and for as many as 30% of tumors seen 
on imaging studies alone .The prevalence of brain metastasis is thought to be 
120,000-140,000 per year in US5. This disease accounts for 20% of cancer deaths 
annually4. 
                  About 60% of patients with metastatic brain tumors are aged 50-70 
years. More than 20% of patients with systemic disease have brain metastasis on 
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autopsy. About 15% of patients with cancer present with neurologic symptoms 
before their systemic cancer is diagnosed25,27 . Among them, 43-60% have an 
abnormal chest radiograph suggestive of bronchogenic primary or other metastases 
to the lung. In 9%, the CNS is the only site of spread. About 10% of patients with 
proven metastatic disease have no identifiable primary source 5. 
SOURCE OF PRIMARY 
      The most common origins of brain metastases are systemic cancer of the lung, 
breast, skin, or GI tract. In the study conducted by Barnholtz .et al ,the distribution 
of primary cancer was as follows: 48% lung, 15% breast, 9% melanoma, 1% 
lymphoma (mainly non-Hodgkin), 3% GI (3% colon and 2% pancreatic), 11% 
genitourinary (21% kidney, 46% testes, 5% cervix, 5% ovary), 10% osteosarcoma, 
5% neuroblastoma, and 6% head and neck tumor 5. 
       Primary lung tumors account for 50% of all metastatic brain tumors. Lung 
cancer is the most common origin of metastatic disease. Of lung cancer patients 
who survive for more than 2 years, 80% will have brain metastases20,24  . 
           The average time interval between the diagnosis of primary lung cancer and 
brain metastases is 4 months. Interestingly, small cell carcinomas, which are only 
20% of all lung cancers, account for 50% of brain metastases from lung cancer22.. 
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             Breast tumor is the main source of metastatic disease in women, followed 
by melanoma, renal, and colorectal tumors 5. The interval between the diagnosis of 
primary breast cancer and brain metastasis can be up to 3 years.  HER positive 
cancer is twice as common to metastasize to the brain. Additionally, it has been 
shown that nm23 and CD44 in breast cancer are indicators for distant metastasis.                
            Melanoma commonly metastasizes to the brain. Melanoma has an 
increased incidence among other systemic cancers in terms of metastasizing to the 
brain. About 40-60% of patients with melanoma will have brain metastasis. 
Melanoma cells are closely related to CNS cells due to their embryonic origin and 
neural crest cells, and they share common antigens such as MAG-1 and MAG-2. 
Approximately 14% of cases have no identifiable primary tumor 33.   
SINGLE/MULTIPLE :     
         Metastatic disease from the breast, thyroid, renal cells, and colon are more 
commonly found as a single metastatic lesion, whereas metastatic disease from 
lung cancer , melanoma and cancers of unknown primary are more commonly 
found to be multiple lesions21,31.  
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INTRACRANIAL SITE OF METASTASES :  
        Both the left side and the right side of the brain were equally represented 
(right 48%, left 46%, and center 6%). The frontal, parietal, and temporo-parieto-
occipital regions were more often involved than the temporal and occipital lobes11. 
Among patients with a single metastasis from a primary tumor situated in the 
pelvis (prostate or uterus) and abdomen (gastrointestinaltract), the incidence of 
infratentorial metastases was 50% , compared with 10%   in patients with other 
primary tumors 1,11. There is a preferential  location  of  metastasis  in the posterior 
border zone (between the middle and posterior cerebral arteries) and in the anterior 
border zone (between the anterior and middle cerebral arteries).  
PATHOLOGY  : 
       Most brain metastases result from arterial tumoral  microemboli , in agreement 
with the rule that emboli tend to pass along the arterial tree as far distally as the 
size permits.  During transient episodes of increased abdominal pressure with 
compression of the vena cava, tumor could seed the spine directly, without 
transiting through the lungs. The cerebral dural sinuses are a direct extension of the 
spinal epidural plexus 26. The pathway is through the basilar plexus of veins to, in 
part, the inferior petrosal sinuses, which are an important outlet for the cerebellum 
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and brain stem.  Metastases via this retrograde pathway could provide an 
explanation for the preferential involvement of the posterior fossa in patients with 
abdominal and pelvic primary tumors27. 
SEX 
         Although melanoma spreads to the brain more commonly in males than in 
females, gender does not affect the overall incidence of brain metastases5,20 . 
AGE 
         About 60% of patients are aged 50-70 years. CNS metastasis is not common 
in children; it accounts for only 6% of CNS tumors in children. Leukemia accounts 
for most metastatic CNS lesions in young patients, followed by lymphoma, 
osteogenic sarcoma, and rhabdomyosarcoma. 
SYNCHRONOUS/METACHRONOUS  DISEASE  : 
       Patients with brain metastasis at the same time of having systemic cancer 
(synchronous metastasis) tend to do worse as compared with patients with 
metachronous metastatic disease25 . 
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PATHOPHYSIOLOGY  OF METASTATIC DISEASE 
                       To metastasize, tumor cells have to gain access to the 
circulation, survive while circulating, pass through the microvasculature of the 
adopted organs, extravasate into the organ parenchyma, and reestablish themselves 
at the secondary site. The tumor cells penetrate the basement membrane and cross 
the subendothelial membrane by producing proteolytic enzymes like 
metalloproteinases and cathepsins. Tumor cells also modulate the expression of 
fibronectin, collagen, or laminin, and change the type of integrin receptor on their 
surface and on the surface of the surrounding stromal cells, resulting in 
desegregation of the stromal cells and creating a permissive environment for them 
to expand and invade. 
         Invading cells detach from the tumor mass, disperse, and traverse the 
epithelial/endothelial boundary. Tumor cells have to survive intravascular 
circulation and avoid immune surveillance during this journey by coating 
themselves with a shield made out of the coagulating elements such as fibrin and 
platelets in the blood. These metastatic emboli also produce adherens to slow 
themselves down to a halt in the blood stream. These adheren molecules allow the 
circulating cancer cells to reattach onto the vascular wall and gain entry to the host 
tissue by disruption of the endothelial barrier. This leads to re-establishment of 
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distant micrometastasis26. When a tumor increases in volume by more than 2-3 
times, the tumor expresses angiogenic factors such as angiopoietin-2 and vascular 
endothelial growth factors. These angiogenic modulators promote sprouting of 
surrounding blood vessels, which results in tumor angiogenesis18,26 . 
               Different tumors metastasize preferentially to different organs. Cells with 
similar embryologic origins are generally believed to have similar growth 
constraints and express similar sets of adhesion molecules, such as addressins. An 
example is melanoma; the cells are closely related to CNS cells (they are derived 
from the neural crest cells), and melanoma commonly metastasizes to the brain. 
Certain cell-surface markers in cancer are indicators and/or predictors of distant 
metastasis, eg, nm23 and CD44 in breast cancer. Similarly, breast cancer cells that 
are HER positive are more likely to metastasis to the brain26. Renal, 
gastrointestinal, and pelvic cancer tend to metastasize to the cerebellum, whereas 
breast cancer is more commonly found in the posterior pituitary33. Thus, the 
trafficking of cancer cells to their final destination is not entirely random and may 
be guided by factors produced by stromal cells of their host organ .   
           The mechanisms by which primary tumors produce brain metastases is 
thought to be hematogenous spread from primary or secondary sites in the lung. 
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Since the brain has no lymphatic system, all tumors metastasizing to the brain do 
so by spreading through the bloodstream. Arterial blood passes through the lungs 
before entering the brain, and collects tumor cells filtered out in capillaries, which 
subsequently embolize to the brain. This is correlated with sites of localization: the 
cerebrum is involved in 80 to 85% of all brain metastases, the cerebellum in 10 to 
15% and the brainstem in 3 to 5% . The overall distribution corresponds roughly to 
the relative size of blood flow regions in the brain26,33 . 
CLINICAL FEATURES: 
                        Approximately 60% of patients with brain metastases have subacute 
symptoms18. Acute onset of symptoms suggests vascular or electrical etiology such 
as bleeding or seizure.  Paraneoplastic syndromes include limbic encephalopathy 
and cerebellar degeneration. The latter is commonly associated with ovarian 
cancer. Progressive weight loss and general fatigue can be ominous and highly 
suggestive of recurrent systemic cancer. Headache (42%) and seizure (21%) are the 
2 most common presenting symptoms14. The other common symptoms are 
cognitive dysfunction(35%) and 30% have motor dysfunction.  
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Physical findings 
           Focal findings are common. Findings consistent with generalized CNS 
dysfunction also can occur secondary to the cumulative effects of multiple CNS 
lesions and edema associated with large single or multiple CNS lesions18 . 
BRAIN METASTASES IMAGING 
        Magnetic resonance imaging (MRI) with contrast enhancement  is the 
procedure of choice, because MRI is more sensitive and specific than other 
imaging modalities in determining the presence, location, and number of 
metastases 1,11. Contrast-enhanced computed tomography (CT) scanning is used 
widely because of easy accessibility and low cost31. Numerous studies have shown 
that contrast-enhanced MRI detects 2-3 times as many lesions as contrast-enhanced 
CT, especially lesions less than 5 mm in diameter. Approximately 20% of patients 
with solitary metastatic lesions on CT show multiple lesions on MRI 1. 
CT BRAIN: 
       Metastases frequently are multiple; they are seen at the junction of gray and 
white matter, usually with significant surrounding edema. On noncontrast CT, the 
density of metastatic lesions may be less than, equal to, or greater than that of 
adjacent brain parenchyma. Most of the patterns are variable and are 
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nondiagnostic. IV administration of contrast material (30-40 g iodine) increases the 
diagnostic accuracy of CT. Most metastases enhance after a standard dose of IV 
contrast. Use of a higher dose of contrast (80-85 g of iodine) and delaying scanning 
by 1-3 hours after injection of the contrast agent lead to a further increase in the 
detection of multiple metastases.  In cases involving a solitary metastatic lesion of 
the brain, detection of an additional lesion may have a bearing on treatment; with 
multiple lesions, surgical treatment may be forgone in favor of chemotherapy or 
radiation therapy 31  . 
                 CT brain has a sensitivity of 92%, a specificity of 99%, and an accuracy 
of 98% in detecting brain metastases. Mostly, the lesions missed on contrast-
enhanced CT were smaller (<2 cm in diameter) and were located next to the bone 
in a frontotemporal location. Dural-based metastases may mimic meningioma. 
MRI BRAIN: 
          Lesions are isointense to mildly hypointense on T1-weighted images; they 
are hyperintense on T2-weighted images or with fluid attenuation inversion 
recovery.Surrounding edema is relatively hypointense on fluid attenuation 
inversion recovery and on T1-weighted images; they are hyperintense on T2-
weighted images11. 
13 
 
 
 
        Hemorrhagic metastases or melanoma lesions are hyperintense on T1-
weighted images. On T2-weighted images, mucinous adenocarcinoma may be 
hypointense, owing to calcification; hemorrhagic metastases may be hypointense, 
owing to the chronic breakdown of blood products. Following administration of a 
contrast agent, solid, nodular, or irregular ring patterns of enhancement are seen. 
Nonenhancing lesions are less likely to be metastases24. 
PET SCAN: 
        With 18-fluorodeoxyglucose (FDG) positron emission tomography (PET) , 
intracerebral metastases may appear as areas of increased metabolism. 
Radionuclide studies are sensitive but are highly nonspecific.  Currently, FDG-
PET is not considered superior to CT or MRI in the initial evaluation of suspected 
brain metastases11. Radionuclide imaging was reported to detect intracerebral 
metastases in approximately 90% of patients, but the findings were nonspecific. 
Neoplasm, inflammation, vascularity, or trauma may cause the abnormal uptake. 
FDG-PET has been reported to detect approximately two thirds of brain metastases 
resulting from systemic cancer. 
 
 
14 
 
 
 
 ANGIOGRAPHY: 
       Angiography currently is not used as a primary diagnostic procedure for 
metastatic disease. Preoperative angiography and embolization of large 
hypervascular metastases from renal and thyroid cancer may be useful. The value 
of angiography  is nonspecific in the diagnosis of metastases24 . 
TREATMENT OF BRAIN METASTASIS 
                             Current treatment options include whole-brain radiation 
therapy (WBRT), surgical resection, stereotactic radiosurgery , and chemotherapy. 
Corticosteroids and antiepileptic medications are commonly used for palliation of 
mass effect and seizures. 
WBRT 
         WBRT is the primary choice for the majority of patients with brain 
metastases. WBRT for brain metastases was first described  50 years ago by Chao 
et al . The RTOG has evaluated a number of different radiation fractionation 
schemes, but median survival seems independent of the dose and schedule2,9 .  
WBRT  is  given in either 10 fractions of 3 Gy over 2 weeks (30 Gy) or 15 
fractions of 2.5 Gy each to a total dose of 37.5 Gy. Accelerated  hyper-fractionated 
regimens delivering up to 70.4 Gy focal radiation offer no additional benefit 
15 
 
 
 
relative to the conventional schedule19 . WBRT reduces symptoms and improves or 
stabilizes overall and neurocognitive function; however, survival with this 
treatment modality alone is poor, and control of brain metastases is achieved in 
only half of patients. 
                Daily fractions >3 Gy likely increase the risk for neurotoxicity. In 
clinical practice, WBRT is commonly delivered to patients with multiple brain 
metastases not amenable to surgery or SRS, poor functional status, or active or 
disseminated systemic disease with effective palliation of neurological symptoms32. 
SIDE EFFECTS :  Significant neurotoxicity has been reported with the use of 
WBRT. Acute effects include hair loss (alopecia), nausea, vomiting, lethargy, otitis 
media and severe cerebral edema. Though some of these effects can be transient, 
dermatitis, alopecia, and otitis media can persist for months after irradiation . 
Chronic effects are even more serious, and these include atrophy, 
leukoencephalopathy, radiation necrosis, neurological deterioration and dementia. 
Reports of development of severe radiation induced dementia have varied between 
11% in one-year survivors  to 50% in those surviving two years2,12 . 
         The use of adjuvant WBRT following resection or radiosurgery has also been 
proved to be effective in terms of improving local control of brain metastases and 
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thus decreasing the likelihood of neurologic death. Approximately 70% of patients 
with brain metastases experience relapse after resection, if WBRT is omitted19. 
           The best evidence from the currently available trials suggests that optimal 
radiation treatment of brain metastases consists of a multimodal approach 
involving a combination of surgery or radiosurgery with WBRT in patients 
stratified by RPA class. In many cases, the addition of WBRT represents a 
conservative approach that can improve local control and delay intracranial 
recurrence19 . 
               Withholding WBRT increases intracranial failure and neurologic 
deterioration is more directly related to disease progression in the brain19 . In the 
recent phase III trial of WBRT with or without motexafin gadolinium, the most 
significant predictor for neurologic and neurocognitive decline, as well as 
deterioration in quality of life, was disease progression in the brain34 .  
WBRT PLUS CHEMOTHERAPY 
                     Several chemotherapeutic agents have been studied in combination 
with WBRT for patients with brain metastases, including chloroethylnitrosoureas, 
tegafur, fotemustine, and teniposide. Although most have shown higher response 
rates in the experimental arm, all have been at the expense of greater toxicity with 
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no benefit in overall survival. The combination of WBRT and low-dose (75 
mg/m2) daily temozolomide (TMZ) has shown promising response rates with 
acceptable toxicity in patients with newly diagnosed brain metastases from a 
variety of solid tumors6 . 
               Various  studies have  shown a  significantly  higher neurological 
progression-free survival rate in the TMZ arm .Several studies have shown 
promising tolerability and response rates for concurrent TMZ and WBRT, 
particularly for non-small cell lung cancer (NSCLC) and melanoma,  but current 
data do not  support the widespread use of the combination in patients with new 
brain metastases. A future treatment strategy may be to assess tumor O6-
methylguanine–DNA methyltransferase methylation status as a way of preselecting 
a group of patients with a greater likelihood of responding to TMZ.  
Prophylactic cranial irradiation: 
            In patients with small cell lung cancer (SCLC), who have a 50% 
estimated 2-year risk for central nervous system (CNS) relapse, PCI reduces the 
risk for brain metastases by 50% and increases overall survival by 16%–18% in 
patients with a clinical response to chemotherapy based on a meta-analysis of 12 
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randomized trials. PCI has also been investigated in high-risk NSCLC patients, and 
there is currently insufficient evidence to support its use in this population32 . 
 SURGERY: 
         Less than 50% of patients with metastatic disease have a single tumor and 
only about 50% of these patients have surgically  accessible  tumors8 . The 
remainder of patients have many tumors or deeply-situated deposits which 
increases the surgical complexity6 .Surgery is an important modality for patients 
with a single brain metastasis, particularly when favorable prognostic factors and 
systemic disease control are present. Surgery significantly reduced brain metastasis 
recurrence and prolonged median survival . Patients  treated  with surgery and 
WBRT  have significantly longer median survival than those who received WBRT 
alone20 . 
              In many studies the surgery plus WBRT arm had a longer median survival 
time (9.2 months versus 3.4 months), higher local control rate (80% versus 48%), 
longer duration of functional independence, defined as a KPS score 70 (38 weeks 
versus 8 weeks), and longer freedom from death resulting from neurological causes 
compared with patients treated with WBRT and biopsy alone20. In patients with 
multiple metastases, surgery is usually limited to patients with a dominant, 
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symptomatic, or life-threatening lesion and/or those who require a tissue diagnosis 
before proceeding with therapy. Recent single-center retrospective studies suggest 
that patients with good prognostic features and two to three metastases may gain 
similar survival benefit from surgery when the dominant lesion is resected13 . 
                The combination of surgical resection followed by WBRT is a more 
effective treatment for control of metastatic brain disease compared with surgery or 
radiotherapy alone20.RPA class 1 patients have median survival times essentially 
double those of patients in RPA class 2 or class 3 when treated with surgery plus 
postoperative WBRT.  
      The complication of surgery are wound infection, pseudomeningocoele 
formation and  thromboembolic complications such as deep vein thrombosis or 
pulmonary embolisms and an operative mortality of approximately 3% 8 . 
RADIOSURGERY 
                 Radiosurgery refers to the delivery of a single large dose of radiation to 
a small intracranial target, using a stereotactic localization system, and maximal 
head immobilization, frequently achieved by using a minimally invasive 
stereotactic head frame. This precise system allows optimal targeting of tumor 
regions while maximally and conformally avoiding healthy brain tissue10. SRS 
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employs multiple convergent beams to deliver a single, large dose of radiation to a 
discrete target volume. The three most common delivery systems are the linear 
accelerator, gamma knife, and cyclotron, which make use of high-energy photons, 
gamma rays, and protons, respectively.  Maximum-tolerated doses of 15, 18, and 
24 Gy have been established by the RTOG 90–05 protocol for tumors 31–40 mm, 
21–30 mm, and 20 mm in maximum diameter, respectively10. 
                 SRS does not address distant failure in the brain. Complications from 
SRS include early treatment-induced edema, reported in 4%–6% of patients within 
1–2 weeks of treatment ; seizures within the first 24–48 hours, reported in 2%–6%]; 
and delayed radiation necrosis, reported in 2%–17%. The risk for radiation necrosis 
increases with larger tumor volume, higher radiation dose, and prior radiotherapy35. 
Combined WBRT plus radiosurgery boost significantly improves control of 
metastatic brain disease in patients with two to four brain metastases10.                         
Chemotherapy 
           Chemotherapy has traditionally played a limited role in the treatment of 
brain metastases and has been reserved for patients who have failed other treatment 
modalities or for diseases known to be "chemosensitive," such as lymphoma, 
SCLC, germ-cell tumors, and, to a lesser degree, breast cancer6 .   
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                 Temozolomide is a recently developed second-generation oral alkylating 
prodrug that is converted to an active metabolite, 5-(3-methyltriazen-
1yl)imidazole-4-carboximide, and has nearly 100% bioavailability. Temozolomide 
readily crosses the blood-brain barrier, producing cerebrospinal fluid 
concentrations that are ∼30% of plasma concentrations. There is some synergy  
with radiation6,34 .Toxicity to temozolomide is general low, with <5% of patients 
experiencing myelosuppression. Temozolomide has shown activity in patients with 
recurrent or newly diagnosed brain metastases from various malignancies. The 
response rate was 24% for non–small-cell lung cancer, 19% for breast cancer, and 
40% for melanoma6. Thus, temozolomide and radiation therapy may have promise 
in patients with brain metastases, especially for those with lung cancer and 
melanoma.  
               Lapatinib a novel targeted drug that can be administered orally and 
inhibits the tyrosine kinase of ErbB1 (epidermal growth factor receptor) and ErbB2 
(HER2) receptors. Similarly gefitinib, an ErbB1 (epidermal growth factor receptor) 
inhibitor, prove efficacious in the treatment of brain metastases6.Approximately 
one third of women with HER2-positive metastatic breast cancer will eventually 
develop CNS metastases. Lapatinib is under investigation, both as a single agent 
and in combination with trastuzumab, in women with metastatic breast cancer34,35 .  
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NSCLC 
             Several chemotherapeutic regimens have modest activity against NSCLC. 
Cisplatin (CDDP) has activity both as a single agent and in combination in patients 
with brain metastases from NSCLC. Response rates of 30% for single-agent CDDP 
and 28%–45% for CDDP in combination with paclitaxel and other agents like 
vinorelbine , gemcitabine, etoposide have been reported13 . 
             Vascular endothelial growth factor pathway inhibitors such as 
bevacizumab and small-molecule receptor tyrosine kinase inhibitors such as 
sorafenib and sunitinib have shown activity in NSCLC and may potentially be 
useful for brain metastases either alone or in combination but  all are entering 
clinical trials only presently34 . 
Breast cancer 
      Objective response rates in the range of 43%–59% have been reported in 
patients with new brain metastases from breast cancer treated with 
cyclophosphamide in combination with 5-fluorouracil (5-FU) and prednisone. 
These regimens may be considered either before or after WBRT in patients with 
newly metastatic breast cancer to brain who have not yet received 
cyclophosphamide-based chemotherapy, particularly in the presence of active 
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systemic disease9. In the recurrent setting, TMZ is the best studied because of its 
favorable BBB penetration, ease of administration, and low toxicity profile. Better 
systemic disease control and survival in patients treated with trastuzumab , and 
poor BBB penetration of trastuzumab, which may provide a "sanctuary site" for 
brain tumor growth while systemic disease is  controlled .  In these patients the 
dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib  has showed modest 
activity in a recent phase II study 15 . 
SURVIVAL AND PROGNOSIS OF METASTATIC DISEASE 
                 Appropriate management of patients with brain metastases requires an 
assessment of independent prognostic factors in order to maximize survival and 
neurologic function whilst avoiding unnecessary treatments. Important variables 
include: age, performance status (most commonly designated by the Karnofsky 
performance status [KPS] score, number of brain metastases (single or multiple), 
primary tumor type (lymphoma, germ cell, and breast versus other), and systemic 
tumor activity (controlled versus uncontrolled). Of these, the KPS score has 
consistently been shown to be the major determinant of survival, secondary only to 
treatment regimen in most studies4 . Time from primary tumor diagnosis to 
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development of brain metastases holds prognostic value as well, particularly for 
breast and melanoma primaries, with long intervals being favorable 15,25.  
          A three-tiered prognostic categorization was derived from 1,200 patients in 
the Radiation Therapy Oncology Group (RTOG) database using recursive 
partitioning analysis (RPA). 
        The overall survival duration for patients in RPA class 1, defined as those 
with a KPS score 70, age <65 years, controlled primary tumor, and no extracranial 
sites of disease, was 7.1 months. The median survival duration was only 2.3 
months for patients in RPA class 3, defined as all patients with a KPS score <70. 
The median survival duration for the remainder, RPA class 2, was 4.2 months 15,16 .   
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KARNOFSKY PERFORMANCE STATUS: 
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AIM OF STUDY 
             
         This  study aims at analyzing the incidence of metastatic brain tumours , 
their distribution, the source of primary, the imaging characteristics, their site 
preference, the various treatment modalities and factors affecting the survival and 
outcome. 
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MATERIALS   AND   METHODS 
MATERIALS     :            All metastatic brain tumour patients reporting to The 
Institute of Neurology and The Department of Radiation Oncology from August 
2008 to January 2011 were included in the study. These patients belong to one of 
the following groups 
1. Patients with biopsy proven primary disease presenting with imaging 
evidence of intracerebral metastasis. 
2. Patients with biopsy proven intracerebral metastasis with known primary. 
3. Patients with biopsy proven intracerebral metastasis with no known source 
of primary 
Patient exclusion criteria  : 
    All patients with neither the primary nor the secondary proven by biopsy 
were excluded from the study. 
 A total of 102 patients qualified for the study. 
OBJECTIVE :   The following factors were studied like 
1. Incidence and Age & sex distribution 
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2. Source of primary according to age and sex 
3. Imaging characteristics of metastatic brain tumours with respect to 
primary. 
4. Clinical features of metastatic brain tumours. 
5. Number of metastatic brain tumours and its relevance to  source of 
primary and survival. 
6. Karnofsky  performance status of the patients with metastatic brain 
tumours and its relevance to survival. 
7. To analyze and predict the overall survival with relevance to age ,KPS, 
source of primary , presence of systemic disease , time interval between 
primary and secondary . 
8. Various treatment options like surgery, WBRT, chemotherapy and their 
effect on prognosis. 
9. Average survival with relevance to primary pathololgy and  karnofsky 
performance status. 
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Type of study: 
                       It is a prospective study and a descriptive study. 
Follow up period : 
              The follow up period ranged from 1week to 2 years, with an 
average of 24 weeks. 
A detailed proforma (Appendix-1) incorporating all the relevant aspects of the 
study was formulated and recorded for each and every patient separately. The 
entire datas were incorporated into a master chart(Appendix-2) and it was 
analyzed by multivariate analysis using SPSS software and chi-square test . 
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RESULTS : 
     There were 102 cases of metastatic brain tumours which fulfilled the inclusion 
and exclusion criteria and they were studied during the period from August 2008 to 
January 2011.  Out of the 102 cases, 90 cases were under regular follow up.12 
cases were lost to follow up during the study period. The follow up percentage is  
88.2%. 
 
AGE  DISTRIBUTION: 
 
TABLE-1-AGE DISTRIBUTION 
Age distribution  No  Percentage 
< 40  15  14.7% 
40 – 69  81  79.4% 
> 70  6  5.9% 
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CHART-1-AGE DISTRIBUTION 
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The youngest person in the study were two 17 year old persons, one with 
Hodgkin’s disease and one with soft tissue sarcoma . The oldest person was aged 
80 years and he was a case of  bronchioalveolar carcinoma lung with brain 
metastases. There were 15 patients in less than 40 age group (14.7%) and 81 
patients in 40 to 69 age group (79.4%) and 6 patients in above 69 age group 
(5.9%). Majority of metastatic brain tumours were in the age group 40 to 69. 
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SEX : 
CHART-2 – SEX DISTRIBUTION 
Male
57%
Female
43% Gender
N = 102
 
 
 
TABLE-2-SEX DISTRIBUTION 
age male female Ratio M:F
<40 3 12 1:4 
40-69 43 38 1.13:1 
>69 4 2 2:1 
total 54 48 1.12:1 
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There were 54 male and 48 female patients with a male:female ratio of 1.12:1. 
There were more females than males in the less than 40 age group with 
male:female ratio 1:4. Whereas in more than 40 age,  there was not major 
difference between incidence in males and females. 
CLINICAL FEATURES: 
            The  average symptom duration before presentation is 10.4 weeks, with 
some cases presenting within a week to some cases presenting as delayed as one 
year. The common clinical presentation is headache  in 69(67.6%), motor 
complaints in 57(55.9%), seizures in 35(34.3%), visual complaints in 7 (6.9%) 
cases, cerebellar features in 12(11.8%) cases. Headache is the most common 
symptom followed by motor deficit and seizures in that order.  
       Clinical evidence of Cerebellar involvement was present in only 46% cases 
with radiological evidence of cerebellar involvement. The clinical presentation  
depends  on the location of intracerebral metastasis. The other clinical features 
(8.8%) include memory disturbances, speech disturbances, disturbed orientation 
and lower cranial nerve palsy.     
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 TABLE -3 CLINICAL FEATURES 
 Symptoms  NO  Percentage
H/V  69  67.6% 
motor/sensory  57  55.9% 
Seizure  35  34.3% 
Visual  7  6.9% 
Cerebellar  12  11.8% 
Others  9  8.8% 
  
CHART-3–CLINICAL FEATURES 
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NUMBER OF METASTASES :    
             Out of the 102 cases 49 were single metastasis and 53 multiple metastases. 
Out of the 49 cases with single metastasis, 44 were under follow up with 14 
alive(30%) and 31(70%) dead. In the multiple metastasis group 46 of the 53 cases 
were under follow up with 12 alive (26%) and 34 dead(73%). In lung primary, 
metastasis was single in 23 cases and multiple in 20 cases and in breast primary , 8 
cases had single metastasis and 7 cases had multiple metastasis. Similarly in 
unknown primary, 9 cases had single metastasis and 14 cases had multiple 
metastases. 
            The distribution of single and multiple metastases among various primary 
groups is given in the Table-5. In this study the incidence of single and multiple 
metastasis is almost similar overall (49:53) and also in lung and breast primary. In 
unknown primary, multiple metastases is common than single metastasis(60.8%). 
In other disease groups, the total number of cases is small to conclude their 
preference for single or multiple metastases. Presence of single or multiple 
metastases was not affecting the outcome independently. 
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CHART-4- NUMBER OF METASTASES 
 
CHART-5-DISTRIBUTION OF NUMBER OF METASTASES 
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TABLE -4 NUMBER OF METASTASIS 
TOTAL  SINGLE MULTIPLE 
102 49 53 
 
TABLE-5  DISTRIBUTION OF METASTASIS 
Source of 
primary 
Number of mets 
Single  Multiple 
Lung  23  20 
Breast  8  7 
Unknown  9  14 
Melanoma  1  0 
Thyroid  2  3 
Lymphoma  0  2 
Renal  1  1 
STS  1  0 
Chorio  1  0 
GIT  2  4 
Ovary  1  1 
Testis  0  1 
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SOURCE OF PRIMARY: 
CHART-6.SOURCE OF METASTASES 
 
CHART-7.AGE GROUPAND SOURCE OF METASTASES 
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TABLE-6.  SOURCE OF METASTASES 
Source of 
metastasis 
Age group 
< 40  40 ‐ 69  >70  total
Lung  0  40  3  43
breast  9  6  0  15
unknown  2  19  2  23
melanoma  0  1  0  1
thyroid  0  5  0  5
lymphoma  1  0  1  2
Renal  0  2  0  2
STS  1  0  0  1
chorio  1  0  0  1
GIT  0  6  0  6
Ovary  0  2  0  2
Testis  1  0  0  1
 
                 The most common source of primary is lung cancer(43), followed by 
unknown primary(23) and breast cancer(15) (Table6/Chart6). Lung is the most 
common source of primary (42%) overall and also in both sexes. It is the most 
common primary in all age groups except less than 40 where breast is the common 
primary. There were 43 lung primary, with no cases in less than 40 age group. Out 
of the 15 cases with breast primary, 9 cases(60%) were below 40 years group and 6 
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cases (40%) were in 40-69 age group.  In unknown primary, 82.6% cases were in 
the age group 40-69 and 2 cases were each in below 40 years and greater than 69 
years. 
       Among lung primary, 17  cases were small cell carcinoma, 10 cases of  
bronchioalveolar carcinoma, 7 cases of adenocarcinoma, 5 cases of squamous cell 
carcinoma and 4 cases of non small cell CA lung. All cases of breast carcinoma 
were infiltrating ductal carcinoma. 
IMAGING APPEARANCE   
              The imaging features of all patients were studied. MRI was done only in 
patients who could afford. Ring lesion is the common appearance of metastasis 
with 51 cases appearing as ring enhancing lesions(50%) (Picture-1). Metastasis had 
cystic appearance in 8 cases(Picture-2) and hemorrhagic appearance in 3 cases 
(Picture-3). In patients with cystic metastasis 3 cases each were from lung 
primary(6.9%) and unknown primary(13%) and 1 each from breast (6.6%)and 
renal primary(50%). There were 3 cases with hemorrhagic lesion one each from 
lung(NSCC), melanoma and choriocarcinoma.  
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TABLE-7.IMAGING APPEARANCE OF METASTASES 
 
Source of 
primary 
Cyst  Hemo  Ring 
contrast 
enhancement 
‐ Homo 
contrast 
enhancement 
‐ Intense 
lung  3  1  24  7  9 
breast  1  0  9  3  4 
unknown  3  0  10  1  5 
melanoma  0  1  0  0  1 
thyroid  0  0  2  1  0 
lymphoma  0  0  0  1  1 
renal  1  0  0  0  0 
STS  0  0  1  0  0 
chorio  0  1  0  1  1 
GIT  0  0  2  1  1 
ovary  0  0  2  0  0 
testis  0  0  1  0  0 
total 8 3 51 15 22 
 
Most of the cases showed heterogenous contrast enhancement, while only 15 cases 
(14.7%) showed homogenous intense contrast enhancement (Picture-4). 
Disproportionate edema (severe edema) was found in 14 cases and minimal to no 
edema in 14 cases. Remainder of the cases excibited mild to moderate edema. In 
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metastatic disease with breast primary, 10 of the 15 cases  had no to mild 
edema(66%), whereas with lung and unknown primary edema factor was variable. 
Edema was very minimal in the two lymphoma cases studied. The imaging 
characteristics of various primaries and the edema component is distributed as 
shown in  Table-7/Table-8 . Edema in imaging is also not specific to any source of 
primary(Chart-8). 
CHART-8.EDEMA IN IMAGING 
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TABLE-8. EDEMA IN IMAGING 
 
 
Source of 
primary 
Edema 
No  Mild  Moderate  Severe 
lung  5  20  11  7 
breast  2  8  5  0 
unknown  4  8  6  5 
melanoma  0  1  0  0 
thyroid  0  2  2  1 
lymphoma  2  0  0  0 
renal  0  0  1  1 
STS  0  1  0  0 
chorio  0  1  0  0 
GIT  1  1  4  0 
 ovary  0  1  1  0 
testis  0  0  1  0 
total 14 43 31 14 
 
SITE OF METASTASES: 
                  Frontal lobe was involved in 66 cases (64%), parietal lobe in 47 cases 
(46%), occipital lobe in 22 cases(21%), temporal lobe in 18 cases (17.6%), 
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cerebellum in 26 cases (25%)and other location like internal capsule(3), basal 
ganglia(8), thalamus(3), brainstem(1) in total 18 cases(Table-9/Chart-9). 
CHART-9. SITE OF METASTASES 
 
       The right hemisphere was involved in 37cases, left hemisphere in 30 cases and 
bilateral hemispheric involvement in 37 cases. Posterior fossa was involved in 33% 
of breast primary and 39% of unknown primary and in 20.5% of lung primary. 
           The most common location is frontal followed by parietal, cerebellum, 
occipital and temporal. The hemispheric involvement was almost similar with 
equal cases involving right and left hemisphere. In this study renal, GIT, pelvic 
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cancer metastasize to cerebellum in 45%, but the total number of the above 
primaries are less to be statistically significant. 
TABLE-9.SITE OF METASTASES 
Source of 
primary  Frontal  Parietal  Occipita Tempora Cerebell Peculiar 
Lung  31  21  8  6  9  7 
Breast  7  7  2  2  5  2 
Unknown  12  12  7  3  8  6 
             
Melanoma  1  0  0  0  0  0 
Thyroid  4  2  1  1  0  1 
Lymphoma  2  1  0  1  0  0 
Renal   0  1  0  0  1  1 
STS  0  0  1  0  0  0 
Choriocarcinoma  1  0  0  0  0  0 
GIT  5  2  1  4  2  1 
Ovary  2  0  0  0  1  0 
Testis  
1  1  1  0  0  0 
Total  66 47 21 17 26 18 
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FACTORS  AFFECTING SURVIVAL 
SYSTEMIC DISEASE: 
TABLE-10.  SYSTEMIC DISEASE & SURVIVAL 
Systemic 
disease 
KPS – Good  KPS ‐ Bad 
P‐value 
Alive  Death  Alive  Death 
Yes  4  2  3  16 
0.838 
No  10  10  9  36 
 
CHART-10. SYSTEMIC DISEASE 
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         The presence of systemic tumour activity other than intracerebral  metastasis, 
as evidenced by imaging  was present in 29 cases , no systemic tumour activity in 
73 cases. In patients with systemic tumour activity, 25 cases were under follow up 
with  7 cases alive (28%).  In patients without systemic tumour activity, 65 cases 
were under follow up with 19 alive (29%). There was not difference in both the 
groups in terms of survival. Presence or absence of systemic tumour activity at 
presentation is not significantly associated with performance status and it was not 
an independent factor for survioval (Table-10/Chart-10) 
SOURCE OF METASTASIS 
       In this study, breast primary had a survival rate of 58.3% (Table-11) . When 
breast primary is correlated with  performance status, it  is not significantly 
associated in predicting overall survival(Table-12) and survival at 3months and at 
6months. Breast primary patients irrespective of their performance status had a 
100% 3months and 6 months survival rate (Table-13). 
         Lung primary had a survival rate of 24.3% (Table-11). When lung primary is 
correlated with performance status, it is not significantly associated in predicting 
overall survival (Table-12) and survival at 3 months and 6 months(Table-14). 
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        Unknown primary had a  23.8% survival rate (Table-11).  Perforamance status  
significantly predicts overall survival (Table-12) and survival at 3months and 
6months in metastatic disease with unknown primary(Table15).There were 2 cases 
of lymphoma with both of them alive during the study period (survival rate of 
100%) . Patients with GIT primary had a survival rate of 40%, but the total number 
in these groups is less, to be statistically significant.The average survival in weeks 
for lung, breast, unknown primary are 21, 52.6 and 28 weeks respectively. 
TABLE -11. DISEASE SPECIFIC SURVIVAL 
Source of primary  Alive  Death  Percentage alive
lung  9  28  24.3%
breast  7  5  58.3%
unknown  5  16  23.8%
melanoma  0  1  ‐
thyroid  1  4  20%
lymphoma  2  0  100%
renal  0  2  ‐
STS  0  1  ‐
chorio  0  1  ‐
GIT  2  3  40%
ovary  0  2  ‐
testis  0  1 
‐
   26  64  28.8%
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TABLE-12. SOURCE OF PRIMARY AND SURVIVAL 
 
Source of 
primary 
KPS ‐ Good  KPS ‐ Bad 
P‐value 
Alive  Death  Alive  Death 
           
lung  4  5  5 23 0.106
breast  5  1  2 4 0.079
unknown  3  2  2 14 0.030
 
TABLE-13. BREAST PRIMARY AND SURVIVAL AT 3MONTHS/6MONTHS 
  3months 
breast    total  alive   
goodKPS    6  6
badKPS    5  5
       
  6months 
breast    total  alive   
goodKPS    6  6
badKPS    4  4
 
TABLE-14. LUNG PRIMARY AND SURVIVAL AT 3MONTHS/6MONTHS 
    3months 
  lung  total  dead  P‐value 
  goodKPS  9  1  0.216 
  badKPS  28  9   
 
  6months 
lung  total  dead  P‐value 
goodKPS  6  2 
0.272 
badKPS  24  14 
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TABLE-15. UNKNOWN PRIMARY AND SURVIVAL AT 
3MONTHS/6MONTHS 
  3months 
 
6months 
       
unknown    total  Alive  P‐value      unknown  total  alive  P‐value 
goodKPS    5  5  0.015      GoodKPS  5 5 0.002 
badKPS    16  6        badKPS  14 3  
 
 
PERFORMANCE STATUS: 
          Performance status is determined by the Karnofsky’s performance score. 
Patients were given a a score between 10 -100. In this study patients had a 
performance score between 20 to 90. Patients with performance score 70 and 
above were grouped as good score and 60 and below as bad score. In this study 
there were 32 patients with KFS score of 70 and above and 70 patients with 
karnofsky’s score 60 and below. The total patients in each group is described in the 
Table-16 & Chart-11. About 25 cases had a performance score of 60, 23 cases had 
a performance score of 70 and 19 cases had a performance score of 19. Together 
these three performance scores accounted to 65 % of cases. 
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CHART-11. PERFORMANCE STATUS DISTRIBUTION 
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TABLE -16 . PERFORMANCE STATUS DISTRIBUTION 
KPS  NO 
20  6 
30  5 
40  15 
50  19 
60  25 
70  23 
80  8 
90  1 
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The total patients alive in each Karnofsky score is given in Table-18 & Chart -12. 
The average survival in weeks in each KPS score is given below in Table-17 
 
TABLE-17. KARNOFSKY & SURVIVAL DURATION 
 
          
 
 
 
 
 
 
 
 
           Survival duration is directly dependant on the performance score.  Most of 
the patients had KPS of either 60 or 70. There was only one patient with 
performance score 90. 
KPS Survival 
in weeks 
20  2.5 
30  6.8 
40  9 
50  21.8 
60  23.3 
70  30.2 
80  30.40 
90  104 
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TABLE 18.PERFORMANCE STATUS AND SURVIVAL 
KFS  Alive  Death 
20  1  3 
30  2  3 
40  5  9 
50  6  12 
60  4  16 
70  5  14 
80  2  6 
90  0  1 
 
CHART -12. PERFORMANCE STATUS AND SURVIVAL  
0
2
4
6
8
10
12
14
16
18
20
20 30 40 50 60 70 80 90
1 2
5 6 4 5
2
3
3
9
12 16 14
6
1
Death
Alive
KFS distribution
Fr
eq
ue
nc
y 
in
 n
o
 
54 
 
 
 
The Karnofsky performance status did not predict survival overall (Table-19). This 
is because the follow up duration varied between patients in the same Karnofsky 
score. But the performance score independently and significantly predicted 
survival at 3months , 6months and 1 year. (Table-20). 
TABLE-19-PERFORMANCE STATUS AND SURVIVAL SIGNIFICANCE 
kfs    alive  dead  p value 
good    7  21 
0.66 
bad    18  43 
 
TABLE-20-PERFORMANCE STATUS AND SURVIVAL AT 3 
MONTHS,6MONTHS & 1 YEAR 
    3months    p‐value      6months    pvalue 
kfs    alive  dead    kfs    alive  dead   
good    25  1  0.001  good    20 2 0.000 
bad    38  25    bad    23 32  
 
    1year    pvalue 
kfs    alive  dead   
good    10  8  0.000 
bad    6  45   
 
TREATMENT ; 
          Patients were treated with either WBRT alone, or craniotomy with WBRT, or 
Stereotactic biopsy with WBRT, or craniotomy alone. Patients were chosen for 
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treatment as per guidelines. As  Stereotactic radiosurgery is not available, it was 
not used as a treatment modality. There were 7 persons in whom craniotomy and 
excision alone was performed ,because patients refused RT or patients expired in 
the post operative period. Craniotomy and excision of lesion combined with 
WBRT was administered in 26 cases. WBRT  alone was administered in 59 cases 
and stereotactic biopsy combined with WBRT in 8 cases. In the WBRT alone 
group consists of cases where the primary was proven by biopsy or anyother site of 
metastasis was proven by biopsy.  Chemotherapy was administered in metastatic 
brain tumours with breast, small cell lung, GIT, lymphoma  and ovarian primary. 
         Performance score was not significantly associated with treatment modality 
in predicting overall survival, except in patients treated with WBRT alone 
group(Table-21). The survival of patients with bad performance score was 
increased when craniotomy is combined with WBRT  than craniotomy alone . But  
this association is not statistically significant. Similarly the survival of  patients in 
bad performance score, treated with WBRT combined with craniotomy was better 
compared with WBRT alone (Table-22) and it was statistically significant. 
Treatment modality was not determining the outcome in patients with good 
performance status. 
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TABLE-21-TREATMENT MODALITY AND SURVIVAL 
    KFS‐good  KFS‐bad   
treatment  no  alive  Dead  alive  dead  pvalue 
Craniotomy alone  7  0  0  1  6  0.198 
Craniotomy+WBRT  26  4  3  7  12  0.353 
WBRT alone  59  9  7  4  28  0.000 
Stereotactic BX+ 
WBRT 
8  1  2  0  4  0.212 
 
TABLE-22-COMPARISON OF TREATMENT MODALITIES 
Bad kfs  alive  Dead  P‐value  Bad kfs  alive  dead  P‐value 
Craniotomy  1  6  0.198  Cr+WBRT  7  12  0.0476 
Cr+WBRT  7  12  WBRT  4  28 
 
AGE AND SURVIVAL: 
          Performance status was significantly predicting survival in the 40-69 age 
group (Table-23) . In less than 40 and greater than 69 age group , performance 
status was not predicting survival overall and also at 3 months , 6months and 1 
year(Table-24& Table-25). Less than 40 was associated with a better survival than 
the greater than 70 age group. 
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TABLE-23-  AGE AND SURVIVAL 
 
 
Age  
distribution 
KFS – Good  KFS ‐ Bad 
p‐value 
Alive  Death  Alive  Death 
 
< 40 
5  3  1  3  0.221 
 
40 – 69 
9  8  9  46  0.002 
 
> 70 
0  1  2  3  0.439 
 
Total 
14  12  12  52 
 
TABLE-24. AGE AND SURVIVAL AT 3MONTHS 
3months 
<40  total  alive  P‐value 
goodkfs  8  8 
0.087 
badkfs  3  2 
3months 
>70  total  dead  P‐value 
goodkfs  1  1 
0.273 
badkfs  5  2 
TABLE-25.AGE AND SURVIVAL AT 6MONTHS&1YEAR 
  1year   
<40    total  alive  P‐value 
goodkfs    6  4 
0.673 
badkfs    2  1 
  1year   
>70    total  dead  P‐value 
goodkfs    1  1 
‐ 
badkfs    3  3 
  1year     
age  alive  dead  pvalue    age  alive  dead  pvalue 
<40  9  1 
0.357   
<40  9 1
0.326 
goodkfs  8  0  badkfs  2 1
    6months        1year     
age  alive  dead  pvalue    age  alive  dead  pvalue 
>70  2  3 
0.809   
>70  2 3
0.764 
goodkfs  1  1  badkfs  2 2
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TABLE-26.NUMBER OF METASTASIS AND SURVIVAL 
 
NUMBER 
good 
kfs    bad kfs       
  alive  dead  alive  dead     
single  5  8  9 22 Pvalue‐  0.54
multiple  10  4  4 30 Pvalue‐  0.00
  P‐value  0.76  P‐value  0.58    
 
TABLE-27.NUMBER OF METASTASIS AND SURVIVAL AT 6 MONTHS 
AND 1 YEAR          
 
6months    1year 
single  total  alive  P‐value    single  total  alive  P‐value 
goodkfs  11  10 
0.002   
goodkfs  11 5
0.016 
badkfs  25  9  badkfs  22 2
6months    1year 
multiple  total  dead  P‐value    multiple  total  dead  P‐value 
goodkfs  11  1 
0.007   
goodkfs  6 2
0.005 
badkfs  30  16  badkfs  29 25
               
 
TABLE-28. TIME INTERVAL BETWEEN PRIMARY AND SECONDARY AND 
SURVIVAL 
goodkfs  alive  dead  p‐value    badkfs  alive  dead  p‐value 
simultaneous  6  7  0.002   simultaneous 7 39  0.32
>6months  7  2      >6months  2 8   
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TABLE-29.EDEMA AND SURVIVAL 
 
    KFS ‐ Good  KFS ‐ Bad  P‐value 
    Alive  Death  Alive  Death 
             
NO    3  1  3 5 0.221
Severe    0  1  3 9 0.118
    p‐value  0.002  p‐value  0.059  
 
 
NUMBER OF METASTASES AND SURVIVAL: 
                  Single or multiple metastases was not significantly affecting outcome 
independently. Performance score was predicting overall survival in multiple 
metastases patients but not in single metastasis patients(Table-26). Whereas 
performance score was significantly predicting survival at 6months and 1year in 
patients with both single and multiple metastases(Table-27). 
TIME INTERVAL BETWEEN PRIMARY AND METASTASES: 
                 In this study, patients with simultaneous diagnosis of primary and 
secondary had worse outcome than in patient groups with time interval between 
primary and secondary was more than 6months. This difference in survival was 
observed in only good performance score patients and not in patients with bad 
performance score(Table-28). 
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EDEMA AND SURVIVAL ; 
        When edema was minimal in imaging, patients had better survival when 
compared with patients with image showing severe edema . This difference in 
survival was observation in patients with good performance score and not in 
patients with bad performance score (Table-29). 
         Analyzing the factors affecting survival, age less than 40 , good Karnofsky 
performance status, breast primary were associated with good survival. Age greater 
than 69, poor performance status, lung primary were associated with poor 
survival.Treatment modality did not affect outcome independent of performance 
status. But surgery combined with WBRT had better survival than RT alone in 
poor performance status patients 
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PICTURE-1-RING LESION 
 
 
 
PICTURE-2-CYSTIC METASTASIS 
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PICTURE-3-HEMORRAGHIC METASTASIS 
 
 
PICTURE-4-INTENSE CONTRAST ENHANCEMENT 
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DISCUSSION : 
AGE 
       Majority of metastatic brain tumours were in the age group 40 to 69. This is 
similar to that described in literature .  The age distribution is almost similar to the 
metropolitan Detroit cancer surveillance system5 .  
SEX 
      There were 54 male and 48 female patients with a male:female ratio of 1.12:1. 
Females out-numbered males in less than 40 age group with male:female ratio 1:4. 
There is not much difference in sex distribution similar to previous studies14,18 . 
CLINICAL FEATURES: 
      The average symptom duration before presentation is 10.4 weeks with some 
cases presenting as early as 1 week to some cases presenting as delayed as one 
year. This is in concordance with previous studies where the average time interval 
between the diagnosis of primary cancer and brain metastases is 4 months18 . 
Similar to what is described in literature, headache is the most common symptom 
followed by motor deficit and seizures in that order14 . Clinical evidence of 
Cerebellar involvement was present in only 46% cases with radiological evidence 
of cerebellar involvement. The clinical presentation  depends  on the location of 
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intracerebral metastasis. The other clinical features (8.8%) include memory 
disturbances, speech disturbances, disturbed orientation and lower cranial nerve 
palsy. There was not much difference between what is observed in this study and 
literature . 
SOURCE OF PRIMARY: 
        The most common source of primary is lung cancer, followed by unknown 
primary and breast cancer. Lung is the most common source of primary (42%) 
overall and also in both sexes. It is the most common primary in all age groups 
except less than 40, where breast is the common primary. In the metropolitan 
Detroit cancer surveillance system study5 , breast is the most common primary in 
females. But in our study even in females lung is the most common source of 
primary. Melanoma though the 2nd common source of metastasis in western 
literature5, is rare in this study.  About  60% of breast metastasis incidence, 
occurred in the less than 40 age group.  
       Among lung primary, 40% of the cases were small cell carcinoma. Similarly it 
was observed in previous studies that, small cell carcinomas, which are only 20% 
of all lung cancers, account for 50% of brain metastases22.. Infiltrating ductal 
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carcinoma is the only  breast primary producing intracerebral metastases in this 
study. 
NUMBER OF METASTASIS : 
                    In this study the incidence of single and multiple metastases is almost 
similar overall (49:53) and also in lung and breast primary. In unknown primary 
multiple metastases is common than single metastasis(60.8%).  Metastatic disease 
from the breast, thyroid, renal cells, and colon are more commonly found as a 
single metastatic lesion, whereas metastatic disease from lung cancer, melanoma 
and cancers of unknown primary are more commonly found to be multiple lesions 
in some studies22 . This is not observed in this study except in unknown primary 
where multiple metastases is common. 
IMAGING APPEARANCE  : 
            Majority of brain metastasis  (50%) were ring enhancing lesions(picture-1). 
Cystic appearance that is common in adenocarcinoma secondaries, colon cancer, 
renal tumours as described in literature11 is not observed in this study. Cystic 
appearance was present in lung, renal and unknown primary and they accounted to 
only 8 cases(picture-2). Hemorrhagic appearance was observed in melanoma and 
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choriocarcinoma secondaries (picture-3) as described in literature, but the total 
number is small to suggest a statistical significance. 
         Majority of lesions exhibited heterogenous and moderate contrast 
enhancement. Intense homogenous contrast enhancement is seen in 15% only 
(picture-4) and does not show any source specificity. 
        In most of the cases of brain metastasis there was only mild to moderate 
edema. Severe or disproportionate edema was present in only 13.7% cases, 
whereas in previous studies it was found that cerebral metastases had 
disproportionate edema28 . Cerebral  Edema in imaging is also not specific to any 
source of primary.  
SITE OF METASTASIS : 
           The most common location is frontal followed by parietal, cerebellum, 
occipital and temporal. The other location include internal capsule(3), thalamus(3),  
brainstem(1) and  basal ganglia(8). The hemispheric involvement was almost 
similar with almost equal cases involving the right hemisphere, left hemisphere or 
both hemispheres. The site of intracerebral metastases is similar to described by 
Schaefer.et.al . Posterior fossa was involved in 33% of breast primary and 39% of 
unknown primary and in 20.5% of lung primary. In literature renal, 
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gastrointestinal, and pelvic cancer tend to metastasize to the cerebellum, whereas 
breast cancer is more commonly found in the posterior pituitary11 . In this study 
renal , GIT, pelvic cancer metastasize to cerebellum in 45%, but the total number 
of the above primaries are less to be statistically significant. There was no case of 
metastasis to the pituitary. 
FACTORS  AFFECTING SURVIVAL:  
SYSTEMIC DISEASE; 
       In patients with systemic tumour activity in addition to brain metastasis as 
evidenced by imaging 28% were alive and in the patients with no evidence of 
systemic disease 29% alive. Systemic tumour activity is not associated with KPS in 
predicting survival and not an independent factor for survival . This is in 
contradiction to the RTOG trial were uncontrolled systemic disease was an 
independent factor affecting survival. In this study systemic tumour activity was 
determined only by imaging like CT or MRI. PET scan , radioiodine scan , tumour 
marker study were not done due to unavailability and extra cost . Considering that, 
when these investigations were performed , as in the RTOG trial ,then the actual 
incidence of systemic tumour activity might have changed .  
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SOURCE OF METASTASIS: 
          Breast primary has 58.3%  survival rate  and performance status is not 
significantly associated with breast primary in predicting  overall survival and 
survival at 3months and at 6months. Breast primary patients irrespective of their 
performance status had a 100% 3monthsand 6 months survival rate. Similar 
findings was observed by Sperduto.et.al in  their multi-institutional analysis of 
4,259 patients. 
         Lung primary has 24.3% survival rate and performance status is not 
significantly associated with lung primary in predicting  overall survival and 
survival at 3 months and 6 months.Unknown primary has 23.8%survival rate  and 
perforamance status  significantly predicts overall survival and survival at 3months 
and 6months in metastatic disease with unknown primary. Unknown primary being 
an individual good prodnostic factor as described by Sperduto.et.al is not observed 
in this study 30  .  
     Lymphoma patients had good overall survival and also patients with GIT 
primary, but the total number of cases, in these groups is less to be statistically 
significant.The average survival in weeks for lung, breast, unknown primary are 
21, 52.6 and 28 weeks respectively. 
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PERFORMANCE STATUS: 
     Performance status is determined commonly  by the Karnofsky’s performance 
score . The other scoring systems like the RPA also predict the overall survival. 
Most of the patients had KPS of either 60 or 70. 81% patients had performance 
score between 40 and 70. Survival duration is directly proportional to the 
performance score.    
                     The Karnofsky performance status did not predict survival overall, 
this is because the follow up duration varied between patients in the same 
Karnofsky score.  But the performance score significantly predicted survival at 
3months , 6months and 1 year and an independent factor for survival as described 
inprevious studies. 
TREATMENT MODALITY : 
         The survival of patients with bad KPS was higher when craniotomy was 
combined with WBRT than  craniotomy alone. But this difference was not 
statistically significant. The survival of  patients in bad KPS score treated by 
WBRT combined with craniotomy had better survival significantly than WBRT 
alone . Treatment modality was not determining the outcome in patients with good 
performance status. This finding is similar to that I literature were patients  treated  
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with surgery and WBRT  had significantly longer median survival than those who 
received WBRT alone20 . Similarly the combination of surgical resection followed 
by WBRT is a more effective treatment for local control of metastatic brain disease 
compared with surgery or radiotherapy alone20 . 
AGE AND SURVIVAL: 
          Performance status was significantly predicting survival in the 40-69 age 
group . In age group less than 40 and above 69 , age itself was a predictive factor 
for survival than performance status. 
NUMBER OF METASTASIS AND SURVIVAL: 
                  Single or multiple metastases was not significantly affecting outcome 
independent of performance status. Performance score was predicting survival 
significantly at 6months and 1year in both single and multiple metastases. This is 
contrary to some studies where multiple metastases was associated with poor 
outcome independent of the performance status29,30 . 
TIME INTERVAL BETWEEN PRIMARY AND SECONDARY: 
                 There was significant difference between patients, with simultaneous 
diagnosis of primary and secondary group having worse outcome than patients in 
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whom the interval between primary and secondary was more than 6months. This 
difference is observed in only good performance score patients and not in patients 
with bad performance score. 
EDEMA AND SURVIVAL ; 
        When cerebral edema was minimal in imaging patients had better survival 
when compared with severe edema . This observation is for patients with good 
KPS and in patients with bad performance status the edema factor was not 
contributing to overall  survival. Thus in good performance score patients factors 
like cerebral edema in imaging and time interval between primary to secondary 
diagnosis were having an effect on the overall survival. Whereas in patients with 
bad performance score, performance status was the better predictor of overall 
survival. 
           Thus when analyzing the factors affecting survival, age less than 40, good 
Karnofsky performance status, breast primary were associated with good survival. 
Age greater than 69, poor performance status, lung primary were associated with 
poor survival. Presence of Systemic disease was not affecting the outcome 
significantly, so does the number of metastases. Karnofsky score was a better 
predictor of survival individually in age 40-69, unknown primary, single or 
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multiple metastases. Treatment modality did not affect outcome independent of 
performance status. But surgery and RT had better survival than RT alone in poor 
performance status patients. 
          Edema in imaging and time interval between primary and secondary carry  
significance only when patients are in good performance score. When patient is 
moribund, performance score  is  the more significant factor in predicting survival. 
         Certain investigations like PET scan, bone scan, radio iodine thyroid scan, 
tumour markers were not done due to non availability and additional cost. So the 
actual incidence of systemic tumour activity could be more than reported in this 
study. Though the presence of  multiple metastases was detected in CT brain itself 
in most of the cases and in only a few cases MRI picked up additional lesions in 
patients with single metastasis, MRI brain was not done routinely in all patients 
because of additional cost. . Though streotactic radiosurgery with WBRT has good 
survival and local control rates, as reported in some studies, SRS was not 
performed in this study because of non availability. 
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CONCLUSION : 
    In this study of 102 patients with brain metastases, the following conclusions 
were derived 
1. Metastatic disease is common in 40-69 age group. 
2. It has equal male female distribution, except in less than 40 age group, in 
which it is common in females. 
3. Headache is the most common symptom followed by motor deficit.  Clinical 
evidence is seen in less than 50% cases with actual incidence of cerebellar 
involvement. 
4. Lung is the most common source of primary in both sexes and in all age 
groups except in less than 40 age. 
5. Breast is the most common source of primary in less than 40 age group. 
6. Majority of brain metastases are ring enhancing with moderate edema. 
Cystic or hemorrhagic appearance is  less common and doesnot show 
disease specificity. 
7. Frontal lobe is the most common site of metastases, with both hemispheres 
equally involved.  Site of intracranial metastases is not disease specific. 
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8. The incidence of single or multiple metastases is almost equal overall and 
with regard to the source of primary. 
9. Age less than 40, good Karnofsky performance status, breast primary were 
associated with good outcome 
10. Age greater than 69, poor performance status, lung primary were 
associated with poor outcome. 
11.  Presence of  Systemic disease  is not an independent factor for survival, so 
does the number of metastases.  
12. In age 40-69, unknown primary, single or multiple metastases, Karnofsky 
score was a better predictor of survival. 
13.  Treatment modality did not affect outcome independent of performance 
status. But surgery and RT had better survival than RT alone in poor 
performance status patients. 
14. Edema in imaging and time interval between primary and secondary 
significantly affected outcome only when patients are in good performance 
score. When patient is moribund, performance score  is  the most 
significant factor in predicting survival. 
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                             APPENDIX-1 
A STUDY OF PROFILE OF METASTATIC BRAIN TUMOURS 
NAME:                                                                                IP NUMBER: 
AGE:        SEX:                                                                    MIN NUMBER: 
Address:                                                                                                   phone no: 
CLINICAL FEATURES: 
        HEADACHE: (y/n)‐‐‐‐‐‐  DURATION‐‐‐‐‐‐‐‐‐‐‐ 
        MOTOR      :(Y/N)‐‐‐‐‐‐  DURATION‐‐‐‐‐‐‐‐‐‐‐ 
        SEIZURES   :(Y/N)‐‐‐‐‐‐  DURATION‐‐‐‐‐‐‐‐‐‐‐ 
        VISION       :(Y/N)‐‐‐‐‐‐  DURATION‐‐‐‐‐‐‐‐‐‐‐ 
     CEREBELLAR(Y/N)‐‐‐‐‐‐‐  DURATION‐‐‐‐‐‐‐‐‐‐‐ 
        OTHERS     :(Y/N)‐‐‐‐‐‐  DURATION‐‐‐‐‐‐‐‐‐‐‐ 
IMAGING : 
  SINGLE/ 
MULTIPLE 
TYPE OF 
METASTASIS 
PLAIN CONTRAST ENHANCEMENT  EDEMA  OTHERS 
CT               
MRI               
 
INVESTIGATION: 
CT CHEST/CT ABDOMEN:                                                                          
USG ABDOMEN:                                                                               OTHERS: 
USG BREAST: 
TREATMENT; 
PRIMARY—:‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 
SECONDARY:‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 
STEREOTACTIC  SURGERY:‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 
WBRT  :‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 
CHEMOTHERAPY:‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 
FOLLOW UP :‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 
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